Mesoblast Limited · ASX:MSB
Mesoblast — Shareholder Meeting (November 2005)
24 slides from Mesoblast's shareholder meeting presentation, Nov 15, 2005
Slide 1: Today's Commercial & Clinical Reality
mesoblast the adult stern cell company Today’s Commercial & Clinical Reality 15 November 2005
Slide 2: Our vision — a world leader in the treatment of orthopedic disease
a pmesoblast the edllt steer cell company our vision — a world leader in the treatment of orthopedic disease Mesoblast's vision is to become a world leader in the definitive treatment of orthopedic conditions. Our immediate focus is to rapidly commercialise our unique and patented adult stem cell te
Slide 3: Agenda
mesoblast the edllt steer cell company agenda * why mesoblast? — a strong business model * what have we got? - a platform stem cell technology * who are our competitors - we have a unique position * how do we protect our position? — a structured IP strategy * what's the market? — massive unmet deman
Slide 4: Why Mesoblast?
a pmesoblast the edllt steer cell company why mesoblast? a strong business model: an adult stem cell platform technology potential for profits equal to pharmaceuticals low to no entry barriers to medical community substantial short term revenue opportunities
Slide 5: Slide 5
Slide 6: Adult stem cells are multipotent
mesoblast the edllt steer cell company adult stem cells are multipotent Mesenchymal Orthopaedic pene Precursor Cell, MPC . MPC Isolated cartilage and Cultured — ak iecracn ‘ : Ey other cell types nt Non-immunogenic \ “ea at heart muscle Adult Stem Cell — Allogeneic use Cardiac Self-Renewing <r" musc
Slide 7: Our cells deliver an efficient high margin business
a pmesoblast the adult stent cxf conpasyy our cells deliver an efficient high margin business: a platform stem cell technology for multiple markets * safe * — universal donor * doses for hundreds/thousands * up to 1000 fold purer initial stem cell pool ~ greater potency * — multiple orthopaedic indi
Slide 8: What's the competitive landscape?
mesoblast the edllt steer cell company what's the competitive landscape? a unique position
Slide 9: Competitive landscape — adult stem cells
a pmesoblast the edllt steer cell company competitive landscape — acult stem cells other stem cell developments use: * — mixed populations of stern cells * whole tissue preparations * autologous (patients own) cells * separation devices * less efficient isolation and culture methods - density gradie
Slide 10: How do we protect our position?
a pmesoblast the edllt steer cell company how do we protect our position? a structured IP strategy
Slide 11: Strong intellectual property
a pmesoblast the edllt steer cell company strong intellectual property a broad based “barrier strategy” to protect our IP and to create a dominant market position * adult stem cell (mesenchymal precursor cell) “ownership” ~ efficient isolation —~ composition of matter * methods of expansion and diff
Slide 12: What's the market?
mesoblast the edllt steer cell company what's the market? massive unmet demand
Slide 13: Stem cells for regenerative medicine — a clear commercial driver
a pmesoblast the edtilt steer ce company stem cells for regenerative medicine — a clear commercial driver market characteristics * massive unmet needs * expanding patient population * increased quality of life at a lower cost * physicians seeking better/safer treatment regimes
Slide 14: Markets are demanding a generational improvement
a p mesoblast the edllt stern ext conpaacyy markets are demanding a generational improvement market drivers * current treatments focus on the two ends of the treatment spectrum: — symptom and pain control (pharma); and —- replacement (device) * current therapies in selected markets: — not curative;
Slide 15: Multiple near term partnership opportunities exist
a p mesoblast the edule stent cel! compasgy multiple near term partnership opportunities exist * commercial partners produce complementary FDA approved products cements/polymers vertebral cages biological stimulants fracture repair devices delivery matrices * catheters * major device companies * maj
Slide 16: Our markets are large unmet indications
a p mesoblast the edtilt steer cel? company our markets are large unmet indications ANNUAL ECONOMIC ANNUAL COST OF BURDEN MEDICAL CARE (USD BILLION) (USD BILLION) BONE FRACTURES USD13b USD 2.3b (materials only) CARTILAGE USD65b USD15b (OSTEOARTHRITIS) SPINAL USD100b USD 9b HEART FAILURE USD 254.8b U
Slide 17: What drives us?
mesoblast the edllt steer cell company what drives us? milestones, outcomes global success
Slide 18: We're on track to deliver
mesoblast the edllt steer cell company we’re on track to deliver clinical protecol/ethics aes GMP process (allo) safetyitox(allo animals) a »- australian human triais ° arthopacdic (auto) « cardiovascular (auto) FOAAND filing * orthopaedic (allo) + cardiovascular (allo) IN aeerovalLS Wwiele | | 5 20
Slide 19: Road to United States FDA commercial approvals for a stem cell product
a pmesoblast the edllt steer cell company road to United States FDA commercial approvals for a stem cell product * optimize ex vivo culture process in GMP facility * perform safety and dose-ranging studies in appropriate large animal model (e.g sheep) * determine best route of administration in larg
Slide 20: Benefits of Australian pilot trials using patient's own cells
a pmesoblast the edllt steer cell company benefits of Australian pilot trials using patient's own cells ° optimize ex vivo culture process . determine optimal cell dose for safety/efficacy . maintain careful registry of adverse events . obtain early efficacy data and validation of technology . enabl
Slide 21: Pilot trial of autologous MPC for non-union tibial fractures
a pmesoblast the edllt steer cell company pilot trial of autologous MPC for non-union tibial fractures = Royal Melbourne Hospital, Australia « trial set to start imminently = up to 10 patients with non-union tibial fractures = no alternative options for patients = own MPC extracted and culture/expan
Slide 22: Pilot trial of autologous MPC for ischaemic heart disease
a pmesoblast the edllt steer cell company pilot trial of autologous MPC for ischaemic heart disease = John Hunter Hospital, Newcastle, Australia « trial set to start imminently = up to 10 patients with multivessel coronary artery disease = no alternative options for patients = own MPC extracted and
Slide 23: Global success
a pmesoblast the edllt steer cell company global success a business model that can provide global success and shareholder returns ° proprietary platform technology — long term protection . multiple applications that can deliver pharma range profit margins ° target large unmet medical needs ° no barr
Slide 24: Questions
by Le mesoblast the adult stern cell company Questions 15 November 2005